ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Nov 16, 2020||ENDRA Life Sciences Reports Third Quarter 2020 Financial Results and Provides Business Update|
|Nov 12, 2020||ENDRA Life Sciences Installs First TAEUS(R) System and Begins Scanning at Rocky Vista University|
|Nov 12, 2020||ENDRA Life Sciences Inc. to Present at the virtual Fall Investor Summit on November 16th-18th|
|Nov 11, 2020||ENDRA Life Sciences to Showcase TAEUS(R) Technology at Two Upcoming Medical Meetings|
|Nov 05, 2020||ENDRA Life Sciences to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Monday, November 16, 2020 at 4:30 p.m. ET|
|Day Range||0.8300 - 0.9000|
|52 Week Range||0.5990 - 2.2500|
|Bid/Ask||0.8456 / 0.8500|
|Bid/Ask Size||200 X 1,700|
|Market Cap||21.35 million|
|Shares Outstanding||25.1 million|
|Dividend/Yield||0.0000 / 0.0000%|
|P/E Ratio (TTM)||N/A|